Safety of 6% hydroxyethyl starch 130/0.4 in reducing ascites in patients with liver cirrhosis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000037895

Enrollment

Unknown

Registered

2020-09-04

Start date

2020-09-15

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

6/5000 Cirrhosis of liver

Interventions

Group 1:HES

Group 2:HES

Group 3:Albumin

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. 72 patients with ascites due to cirrhosis were selected; 2. The patients were randomly divided into two groups: group A with sodium lactate ringer and group B with HES. 3. The amount of sodium lactate ringer and hes is 5% of the blood volume calculated by the blood volume formula. 4. Patients in group A were given 5% lactate ringer once a day for 7 days. 5. Patients in group B received 5% HES, once a day, for 7 days.

Exclusion criteria

Exclusion criteria: 1. No severe pulmonary hypertension; 2. Patients without respiratory diseases; 3. Patients with normal liver and kidney function; 4. Patients without history of HES allergy.

Design outcomes

Primary

Measure	Time frame
Blood biochemical indexes;immunological index;	—

Countries

China

Contacts

Public ContactHuang Shaoyan

Yantaishan Hospital

492991401@qq.com+86 15506636262

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026